From: gts (gts_2000@yahoo.com)
Date: Mon Feb 17 2003 - 12:26:55 MST
Rafal,
> ### Good for you! I really have no problem with the promotion of
> deprenyl as a nootropic, since here you present evidence of better
> quality, a double-blind randomized trial.
Well that's certainly a refreshing change of tune from you, Rafal.
A few messages ago you were telling me that this drug was a waste of
time and money. You even suggested indirectly that my way of thinking
could kill people (re: my comparison of DATATOP to the recent halted
study of female HRT).
One of the problems inherent in this discussion (Robert Bradbury, take
note) is that selegiline (deprenyl) is thought to have so many benefits
that it is difficult to pin down. There are many sub-topics worth
debating:
Is it likely to enhance cognitive ability in normal healthy humans?
Is it likely to enhance sex drive in normal healthy humans?
Is it likely to improve mood in normal healthy humans?
Is it likely to protect neurons from neurotoxins and excitotoxins in
normal healthy humans?
Is it likely to improve life-expectancy in normal healthy humans?
My answer is "yes" to all these questions, with varying degrees of
certainty. However my pro-selegiline position would not change even if I
were shown to be wrong about one or two of these questions.
Unfortunately drug companies do not spend R&D money in an effort to
improve the lives of normal healthy humans, so we are forced to base our
opinions on indirect data and personal experience.
-gts
This archive was generated by hypermail 2.1.5 : Mon Feb 17 2003 - 12:27:54 MST